Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies

Diabetes

Volumn 52, Issue 8, 2003, Pages 2160-2167

  Meigs, James B ^a   Wilson, Peter W F ^b   Nathan, David M ^c   D'Agostino Sr , Ralph B ^d   Williams, Ken ^e   Haffner, Steven M ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Boston University   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CORONARY RISK; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SYNDROME X; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CORONARY DISEASE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MASSACHUSETTS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; TEXAS;

EID: 0042266224     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.8.2160     Document Type: Article

References (47)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Stern MP, Haffner SM: Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 6:123-130, 1986
3. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035-2038, 1979
4. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA 263:2893-2898, 1990
5. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P & Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
6. Wilson PW, McGee DL, Kannel WB: Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. Am J Epidemiol 114:697-704, 1981
7. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 45:699-706, 1996
8. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB: Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159:1104-1109, 1999
9. Meigs JB, D'Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594-1600, 1997
10. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152:908-911, 2000
11. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100:123-128, 1999
12. Kekalainen P, Sarlund H, Pyorala K, Laakso M: Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes. Diabetes Care 22:86-92, 1999
13. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M: Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24:1629-1633, 2001
14. Arya R, Blangero J, Williams K, Almasy L, Dyer TD, Leach RJ, O'Connell P, Stern MP, Duggirala R: Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans. Diabetes 51:841-847, 2002
15. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and Classification of Diabetes Mellitus, provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
16. National Cholesterol Education Program: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
17. Kannel WB, Feinleib M, McNamara JR, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 110:281-290, 1979
18. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med 128:524-533, 1998
19. American Diabetes Association: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes 20:1183-1197, 1997
20. Meigs JB, Haffner SM, Nathan DM, D'Agostino RB, Wilson PW: Sample exchange to compare insulin measurements between the San Antonio Heart Study and the Framingham Offspring Study. J Clin Epidemiol 54:1031-1036, 2001
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
22. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW: Diagnosing insulin resistance in the general population. Diabetes Care 24:460-464, 2001
23. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipid lipoprotein fractions. Clin Chim Acta 166:1-8, 1987
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
25. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ: Sex differences in the effect of sociocultural status on diabetes and cardiovascular risk factors in Mexican-Americans: the San Antonio Heart Study. Am J Epidemiol 120:834-851, 1984
26. Stern MP, Patterson SM, Haffner SM, Hazuda HP, Mitchell BD: Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA 262:360-364, 1989
27. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442-443, 1999
28. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease risk using risk factor categories. Circulation 97:1837-1847, 1998
29. Lee J: Covariance adjustment of rates based on the multiple logistic regression model. J Chron Dis 34:415-426, 1981
30. SAS Institute I: SAS/STAT User's Guide. Cary, NC, SAS Institute, 1989
31. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
32. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP: The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282:1519-1522, 1999
33. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
34. Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575-581, 2003
35. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
36. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20:538-544, 2000
37. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
38. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51:3120-3127, 2002
39. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV: Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861-867, 2003
40. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575-581, 2002
41. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
42. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
43. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
44. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isies C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
45. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882-1885, 2001
46. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
47. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998